 |
Influenza Vaccine Composition for the 2016–17 SeasonAll influenza vaccines licensed in the United States will contain HA derived from influenza viruses antigenically identical to those recommended by FDA (451). Both trivalent and quadrivalent influenza vaccines will be available in the United States (Table 1). The 2016–17 U.S. influenza vaccines will contain HA derived from the following:
The 2016–17 U.S. quadrivalent vaccines will contain the same three antigens, and an additional influenza B virus HA, derived from a B/Phuket/3073/2013–like virus (Yamagata lineage). The composition for 2016–17 represents a change in the influenza A(H3N2) virus and a switch in lineage for the influenza B viruses. This season’s recommendations and a full list of references can be accessed at Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2016-17 Influenza Season, MMWR 2016, August 26, 2016 / 65(5);1-54. This season’s recommendations and a full list of references can be accessed at Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2016-17 Influenza Season, MMWR 2016, August 26, 2016 / 65(5);1-54. This season’s recommendations and a full list of references can be accessed at Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2016-17 Influenza Season, MMWR 2016, August 26, 2016 / 65(5);1-54. Syndicated Content Details:
Source URL: http://www.cdc.gov/flu/professionals/acip/app/strains.htm Source Agency: Centers for Disease Control and Prevention (CDC) Captured Date: 2016-07-19 18:33:10.0
|
|